Serological Tumor Markers - Their Role

Chander, Yogesh; Subramanya, H

doi:10.1016/s0377-1237(17)30207-1

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of biomarkers in different tumours is based on their ability to detect, both serologically and histologically, different molecules that have an impact on the diagnosis, prognosis and follow-up of patients with different oncological diseases. The detection of tumour markers such as CA 19-9, CA 125 and CA 15.3 peripherally is such that the higher the level of serological elevation, the greater the tumour burden, the greater the probability of relapse and the worse the prognosis [ 50 , 51 ]. Currently, in osteosarcoma, the diagnosis and evaluation of disseminated disease are based on radiological tests and biopsy.…”

Section: Serological Markersmentioning

confidence: 99%

Towards the Search for Potential Biomarkers in Osteosarcoma: State-of-the-Art and Translational Expectations

Pekarek

Torre-Escuredo

Fraile-Martínez

et al. 2022

IJMS

View full text Add to dashboard Cite

Osteosarcoma represents a rare cause of cancer in the general population, accounting for <1% of malignant neoplasms globally. Nonetheless, it represents the main cause of malignant bone neoplasm in children, adolescents and young adults under 20 years of age. It also presents another peak of incidence in people over 50 years of age and is associated with rheumatic diseases. Numerous environmental risk factors, such as bone diseases, genetics and a history of previous neoplasms, have been widely described in the literature, which allows monitoring a certain group of patients. Diagnosis requires numerous imaging tests that make it possible to stratify both the local involvement of the disease and its distant spread, which ominously determines the prognosis. Thanks to various clinical trials, the usefulness of different chemotherapy regimens, radiotherapy and surgical techniques with radical intent has now been demonstrated; these represent improvements in both prognosis and therapeutic approaches. Osteosarcoma patients should be evaluated in reference centres by multidisciplinary committees with extensive experience in proper management. Although numerous genetic and rheumatological diseases and risk factors have been described, the use of serological, genetic or other biomarkers has been limited in clinical practice compared to other neoplasms. This limits both the initial follow-up of these patients and screening in populations at risk. In addition, we cannot forget that the diagnosis is mainly based on the direct biopsy of the lesion and imaging tests, which illustrates the need to study new diagnostic alternatives. Therefore, the purpose of this study is to review the natural history of the disease and describe the main biomarkers, explaining their clinical uses, prognosis and limitations.

show abstract

Section: Serological Markersmentioning

confidence: 99%

Towards the Search for Potential Biomarkers in Osteosarcoma: State-of-the-Art and Translational Expectations

Pekarek

Torre-Escuredo

Fraile-Martínez

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…The presence of proteins in liquid biopsy in cancer patients was first published in 1847 by Dr. Henry Bence Jones (reviewed in Reference [ 180 ]). Proteins and peptides (protein mass < 15 kDa) might be great candidates as biomarkers, since they are directly related to the “real-time” dynamic molecular cell phenotype.…”

Section: Liquid Biopsy Biomarkers and Their Clinical Applicationsmentioning

confidence: 99%

Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring

Lodewijk

Dueñas

Rubio

et al. 2018

IJMS

View full text Add to dashboard Cite

Bladder Cancer (BC) represents a clinical and social challenge due to its high incidence and recurrence rates, as well as the limited advances in effective disease management. Currently, a combination of cytology and cystoscopy is the routinely used methodology for diagnosis, prognosis and disease surveillance. However, both the poor sensitivity of cytology tests as well as the high invasiveness and big variation in tumour stage and grade interpretation using cystoscopy, emphasizes the urgent need for improvements in BC clinical guidance. Liquid biopsy represents a new non-invasive approach that has been extensively studied over the last decade and holds great promise. Even though its clinical use is still compromised, multiple studies have recently focused on the potential application of biomarkers in liquid biopsies for BC, including circulating tumour cells and DNA, RNAs, proteins and peptides, metabolites and extracellular vesicles. In this review, we summarize the present knowledge on the different types of biomarkers, their potential use in liquid biopsy and clinical applications in BC.

show abstract

Serological Tumor Markers - Their Role

Cited by 2 publications

References 7 publications

Towards the Search for Potential Biomarkers in Osteosarcoma: State-of-the-Art and Translational Expectations

Towards the Search for Potential Biomarkers in Osteosarcoma: State-of-the-Art and Translational Expectations

Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring

Contact Info

Product

Resources

About